[en] Fluoride has been used over the past 25 years as a potential treatment of established osteoporosis. Notwithstanding a consensus over its ability to stimulate bone formation, discrepant results were published relating to its antifracture efficacy. Differences in the published results are likely to be linked to therapeutic regimens, fluoride formulation, and the nature of the treated populations. A critical review of the published data evaluating the antifracture efficacy of fluoride leads to the conclusion that this substance should be mainly used in postmenopausal women with low bone mineral density without prevalent fracture, that low-dose fluoride for a prolonged period should be preferred to high doses for short-term treatment, and that gastroresistant preparations are likely to be better tolerated than fluoride.
Disciplines :
Public health, health care sciences & services
Author, co-author :
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Paul, I.
Gosset, Christiane ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique : aspects généraux
Language :
English
Title :
Current Status of fluoride salts to treat postmenopausal osteoporosis
Cohen P: Fluoride and calcium therapy for myeloma bone lesions. JAMA 1966, 198:583-586.
Reginster JY: Treatment of bone in elderly subjects: calcium, vitamin D, fluor, bisphosphonates, calcitonin. Horm Res 1995, 43:83-88.
Bellows CG, Heersche JNM, Aubin JE: The effects of fluoride on osteoblast progenitors in vitro. J Bone Miner Res 1990, 5:101-105.
Farley JR, Tarbaux N, Hall S, Baylink DJ: Mitogenic action(s) of fluoride on osteoblast line cells: determinants of the response in vitro. J Bone Miner Res 1990, 5:107-113.
Okuda A, Kanehisa J, Heersche JNM: The effects of sodium fluoride on the resorptive activity of isolated ostaclasts. J Bone Miner Res 1990, 5:115-120.
Kanis J: Treatment of symptomatic osteoporosis with fluoride. Am J Med 1993, 95(suppl):S53-61.
Nagant de Deuxchaisnes C, Devogelaer JP, Depreseux G, Malghem J, Maldague B: Treatment of the vertebral crush fracture syndrome with enteric-coated sodium fluoride tablets and calcium supplements. J Bone Miner Res 1990, 5(suppl):S5-26.
Riggs BL, Hodgson SF, O'Fallon WM, Chao EYS, Wahner HW, Muhs JM, Cedel SL, Melton LJ: Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990, 322:802-809.
Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM et al.: Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990, 322:802-809.
Pak CY, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR: Treatment of postmenopausal osteoporosis with slow-release sodium fluoride: final report of a randomized controlled trial. Ann Intern Med 1995, 123:401-408.
Mamelle N, Meunier PJ, Dusan R, Guillaume M, Martin JL, Gaucher A, et al.: Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 1988, 2:361-365.
Meunier PJ, Sebert JL, Reginster JY, Briancon D, Appelboom P, Netter G et al.: Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOS study. Osteoporos Int 1998, 8:4-12. Absence of antifracture effect of fluoride in severely osteoporotic subjects treated for 2 years.
Kleerekoper M, Peterson EL, Nelson DA, Phillips E, Schork MA, Tilley BC, et al.: A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int 1991, 1:155-161.
Delmas PD, Dupuis J, Duboeuf F, Chapuy MC, Meunier PJ: Treatment of vertebral osteoporosis with disodium monofluorophosphate: comparison with sodium fluoride. J Bone Miner Res 1990, 5:143-147.
Reginster JY: Treatment of postmenopausal osteoporosis with sodium monofluorophosphate: preliminary results of a long-term double blind placebo-controlled study. In Osteoporosis 1987. Edited by Christiansen C, Riis B. Aalborg: Handlstrykkeriet Aalborg; 1987:535-537.
Muller P, Schmid K, Warmecke G, Setnikar I, Simon B: Sodium fluoride-induced gastric mucosal lesions: comparison with sodium monofluorophosphate. Z Gastroenterol 1992, 30:252-254.
Reginster JY, Meurmans L, Zegels B, Rovati L, Minne HW, Giacovelli G, et al.: The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. Ann Intern Med 1998, 129:1-8. Report of a reduction in vertebral fracture rates following 4 years of fluoride treatment in women with low bone mass and no previous fractures.
Riggs BL, O'Fallon W, Hodgson S, Chao E, Wahner H, Muhs J, et al.: Clinical trial of fluoride in osteoporotic women: extended observation and additional analyses [abstract]. Bone Miner 1992, 17(suppl):S74.
Parfitt AM: Bone remodeling: relationship to the amount and structure of bone and the pathogenesis and prevention of fractures. In Osteoporosis: Etiology, Diagnosis, and Management. Edited by Riggs BL, Melton LJ III. New York: Raven Press; 1988:45-93.
Delmas PD, Dupuis J, Duboeuf F, Chapuy MC, Meunier PJ: Treatment of vertebral osteoporosis with disodium monofluorophosphate: comparison with sodium fluoride. J Bone Miner Res 1990, 5(suppl):S143-147.
Ericsson Y: Monofluorophosphate physiology: general considerations. Caries Res 1983, 17(suppl):S46-55.
Muller P, Schmid K, Warnecke G, Setnikar I, Simon B: Sodium fluoride-induced gastric mucosal lesions: comparison with sodium monofluorophosphate. Z Gastroenterol 1992, 30:252-254.
Warneke G, Setnikar I: Effects of meal on the pharmacokinetics of fluonde from oral monofluorophosphate. Arzneimittelforschung 1993, 43:592-595.
